Eli Lilly Long Term Investment: The Quiet $1 Trillion Giant Wall Street Still Underestimates

There’s something peculiar about strolling through downtown Indianapolis and discovering that one of the world’s most valuable pharmaceutical companies is housed in the tall limestone building across the canal. Eli Lilly lacks the swagger of a campus in Silicon Valley. No electric shuttles humming between buildings, no glass domes. Just a 150-year-old pharmaceutical company that, while the rest of the market was fixated on AI headlines, quietly grew into a trillion-dollar enterprise.

Finally, investors appear to be taking notice. Over the last five years, Lilly’s stock has increased by more than 400%, transforming patient investors into the type of silent millionaires who never share their wealth online. It’s easy to understand why tirzepatide, the molecule behind Zepbound for obesity and Mounjaro for diabetes, is the clear motivator. The demand story is evident when you walk into any American pharmacy: patients paying cash when their insurance won’t cover it, waitlists, and rationing. Pull-throughs like that are uncommon in the pharmaceutical industry.

By conventional measures, the stock is still not inexpensive. Lilly trades significantly above the overall market at a price-to-earnings ratio close to 40, and it is reasonable to argue that a significant portion of future growth has already been factored in. The possibility that insurers could limit GLP-1 coverage or that Novo Nordisk, Amazon, and a few biotech competitors could erode the moat is raised by skeptics. It’s a legitimate concern. Pharma is replete with tales of businesses that seemed unstoppable until a rival conducted a superior trial or a patent expired.

However, the long-term case is based on more than a single drug class. Cash has been used by Lilly’s management with a level of cool aggression that is uncommon in the sector. The company honestly acknowledged that traditional drug discovery, with its ten-year timelines and billion-dollar flameouts, needs to change when it extended its AI partnership with InSilico Medicine in an early April deal worth up to $2.75 billion. A few days later, Centessa was acquired for about $6.3 billion up front, bringing a promising orexin-receptor program for sleep-wake disorders into Lilly’s neuroscience pipeline. The Kelonia deal came next. In a few weeks, there will be three wagers, each focusing on a distinct aspect of the upcoming ten years.

As this develops, it’s difficult to ignore the contrast with businesses that hold onto successful franchises until the tipping point. Lilly is behaving as though it already knows that the GLP-1 boom won’t last forever and is making use of the windfall to develop plans. The pipeline is wide, not just deep, with Kisunla in Alzheimer’s, Ebglyss in dermatology, and Verzenio still quietly expanding in breast cancer.

Whether Lilly is inexpensive isn’t really the question for long-term investors. It isn’t, not in the traditional sense. The question is whether it is worthwhile to invest in a company that has a protected leadership position in the biggest new drug market in a generation and is compounding earnings at double-digit rates. Threads on Reddit are divided. A few holders from the $700 days are eager to cut. Others sit motionless and quote Peter Lynch.

However, there is a sense that Lilly is evolving from a pharmaceutical company to an operating system for the next stage of healthcare, a half-machine-learning lab, half-manufacturing behemoth. Three shifts are used in the factories outside of Indianapolis. In North Carolina, construction workers are still pouring concrete. The infrastructure being developed around obesity won’t go away, even if the obesity wave eventually subsides.

Whether the next five years will resemble the previous five is still up in the air. They most likely won’t. However, Eli Lilly appears less like a stock to chase and more like one to sit with for investors who are prepared to endure noise, dips, and the odd bad trial. In ten years, you’ll be happy that you didn’t sell too soon.